Industry analysis from MarketsandMarkets indicates that the market valuation will climb from $1.11 billion in 2026. This growth is underpinned by substantial R&D investments from pharmaceutical and biotechnology companies, alongside an increasing demand for specialized proteins in areas like oncology, immunology, and stem cell research. North America remains the dominant region, capturing 43.6% of the market share in 2025 due to its advanced life science infrastructure and established research institutions.
In section Releases
Global Research Use Recombinant Protein Market to Reach $1.55 Billion
The global market for research-use recombinant proteins is set to grow to $1.55 billion by 2031, expanding at a compound annual growth rate of 7.0%. Driven by accelerating drug discovery and complex cell-based research, the sector is evolving to prioritize high-purity, animal-free, and biologically active proteins for laboratory workflows.
Within the product landscape, cytokines and chemokines serve as the primary drivers, accounting for 25.9% of the market. These proteins are essential for cell signaling and differentiation studies. Mammalian expression systems currently lead the host-cell segment, favored for their ability to produce complex proteins with human-like folding and post-translational modifications. Major market players, including Thermo Fisher Scientific, Bio-Techne, and Merck KGaA, continue to compete alongside specialized firms and startups to refine protein stability and lot-to-lot consistency for sensitive experimental applications.
Comments (0)
No comments yet. Be the first!